TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06335615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Acceptance Intervention
Description: The intervention consist of explanations and exercises about acceptance of stress. The intervention starts with a welcome, after which participants do jumping jacks and then breath through a straw to induce an uncomfortable experience. Next, a Chinese finger trap is used to show the automatic, but often not useful, reaction to avoid stress. Participants then watch a short video that introduces the concept of acceptance, and they do a short, guided meditation. Afterwards, they do the straw exercise again, but this time with instruction to examine and allow uncomfortable experiences. The session ends with a recap and the introduction of the home exercise. Participants install an app that reminds them every hour to do a three-second meditation in which they pay attention to their breathing and body in an accepting way.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: In the psychoeducation, participants learn about the stress response, mindfulness, and acceptance. For this, they are guided through a vignette about a student who struggles with stress and then develops a more accepting stance towards it. The psychoeducation explains how acceptance can help to deal with stress but does not instruct participants to apply this in their own life.
Study: NCT04915196

Intervention type: DIETARY_SUPPLEMENT
Intervention: Liposomally-bound Iron
Description: Ferric pyrophosphate microencapsulated in liposomal form is an over the counter natural health product approved by Health Canada and commonly used for iron replacement. If this product is prescribed as part of usual management of iron deficiency and patients consent to participation they will be contacted by telephone survey of gastrointestinal tolerability.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Liposomally-bound Iron
Description: Ferric pyrophosphate microencapsulated in liposomal form is an over the counter natural health product approved by Health Canada and commonly used for iron replacement. If this product is prescribed as part of usual management of iron deficiency and patients consent to participation they will be contacted by telephone survey of gastrointestinal tolerability.
Study: NCT05873985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic tape on experimental group
Description: The dynamic taping application was carried out in 2 stages. Three I-shaped tapes were cut. In the first stage, the person was asked to perform scapular retraction, and in this position, the tape was placed by applying medium tension to the anterior part of the other deltoid muscle, passing from the anterior part of the deltoid muscle to the upper thoracic region. In the second stage, the participant was asked to do scapular retraction and depression, and while maintaining this position, medium tension was applied to the lower thoracic vertebra starting from the anterior part of the deltoid muscle and the acromion and tape was applied. Afterward, this process was applied on the other side

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham tape on placebo group
Description: Sham taping was performed in 2 stages. Three I-shaped tapes were cut. Participants were asked to stand in the comfortable position they used during the day. The first tape was adhered from the starting point of the spine of the scapula with the acromion to the junction of the spine of the scapula and the acromion on the other side without any tension. The other two tapes, starting from the beginning and ending points of the first tape, were adhered to the lower thoracic region without any tension
Study: NCT05352542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GPC3 Targeting CART Cells
Description: before treatment with GPC3 Targeting CART cells, subjects will receive a conditioning regimen
Study: NCT05998915

Intervention type: OTHER
Intervention: observe only
Description: observe only

Intervention type: OTHER
Intervention: observe only
Description: observe only

Intervention type: OTHER
Intervention: observe only
Description: observe only

Intervention type: OTHER
Intervention: observe only
Description: observe only

Intervention type: OTHER
Intervention: observe only
Description: observe only

Intervention type: OTHER
Intervention: observe only
Description: observe only
Study: NCT04947644

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: After negative response, 10 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 5ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided continuous erector spinae plane block
Description: After verifying the correct space with hydrodissection by 5mL of saline 0.9%, lifting erector spinae muscle off the bony shadow of the transverse process, a catheter was inserted was inserted 3 cm beyond the needle tip and 20 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 10 ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
Study: NCT04870073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming
Description: Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming
Description: Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Priming
Description: The conventional priming procedure will be used in the standardized cardiopulmonary machine used at the Hamilton General Hospital.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Priming
Description: The conventional priming procedure will be used in the standardized cardiopulmonary machine used at the Hamilton General Hospital.
Study: NCT04855773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEPmate
Description: PrEPmate is a multi-component mHealth intervention grounded in the information, motivation, behavioral skills (IMB) theory of behavior change and developed through user-centered design. PrEPmate promotes personalized communication between patients and providers through interactive weekly check-in messages asking participants how PrEP is going, allowing navigators to identify patients needing more help in taking PrEP, and customized daily pill-taking reminder messages. Trained PrEP navigators reach out to participants who indicate they need assistance via text or phone call and provide tailored support. Additionally, the platform supports 2-way communication between patients and PrEP navigators, including reminders for upcoming clinic visits. Participants are provided links to key information about PrEP (PrEP Basics), and video testimonials of peers taking PrEP. Messages are available in English and Spanish. PrEPmate is aimed at both patients and PrEP navigators.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dot Diary
Description: Dot Diary is a mobile phone app that integrates an electronic pill-taking and sex diary and delivers real-time feedback on PrEP protection. Using the self-management model to increase self-efficacy and patient empowerment, participants log daily PrEP pill-taking and sexual behaviors in the app, which then provides real-time feedback on the level of protection achieved from PrEP (high, medium, low), and customized instructions on doses of PrEP needed to achieve or maintain high protection. Participants can also view a weekly and monthly calendar, including visualizations of the proportion of sex acts covered by PrEP. Finally, the Dot Diary app incorporates gamification components, including an ability to earn sex-positive badges, to increase engagement. Dot Diary is aimed only at patients.
Study: NCT03554707

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-53
Description: 2.1 mg DNA/m2 or 2.8 mg DNA/m2 twice weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Standard radiation plan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/m2/dose IV daily for five days in a 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100mg/m2 PO daily for five days in a 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg IV every two weeks in a 4-week cycle
Study: NCT05004194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular Caloric Stimulation
Description: Irrigation of the right external ear canal
Study: NCT04698096

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
Study: NCT05013112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Empagliflozin 20mg once daily from discharge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg twice daily from discharge

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group
Study: NCT06490874

Intervention type: DEVICE
Intervention: CGM device - Metformin group
Description: Individuals randomized to metformin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).

Intervention type: DEVICE
Intervention: CGM device - Insulin group
Description: Individuals randomized to insulin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).
Study: NCT04838756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI screening modality
Description: Screen exam will be analysed with an AI system (Transpara, ScreenPoint, Nijmegen, The Netherlands) that assigns exams with a cancer-risk score from 1 to 10, as well as presenting CAD-marks at suspicious findings. Exams with risk score 1-9 will be single read and exam with score 10 will be double read. Risk scores and CAD-marks are provided to the reader(s). The reader(s) will decide whether to recall the woman for work-up or not (as per standard of care). In addition, exams with the highest 1% risk will by default be recalled with the exception of obvious false positives.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional screening modality
Description: Screen exams will be read by two radiologists without the support of AI.
Study: NCT04698096

Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire

Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination

Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination
Study: NCT05952128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib+ Dalpiciclib
Description: Drug Fluzoparib 100mg bid PO qd, administered continuously until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.~Other names: SHR-3162~Drug Dalpiciclib 100mg/125mg/150mg PO qd, administered only from day1 to day 21 every cycle until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.~Other names: SHR-6390
Study: NCT04843683

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Stereotactic ablative radiotherapy (SBRT) is a type of radiation treatment that delivers precise, high dose radiation to targeted areas. In this study, a single treatment of SBRT will be delivered to the abnormal area of a participant's heart that is causing dangerous heart rate and rhythm changes (arrhythmia).
Study: NCT06467136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound production treatment
Description: Evidence based treatment for apraxia of speech, developed by Julie Wambaugh.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound production treatment
Description: Evidence based treatment for apraxia of speech, developed by Julie Wambaugh.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery Practice
Description: Practice of target items using motor imagery during home practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery Practice
Description: Practice of target items using motor imagery during home practice
Study: NCT05324644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: In the first interviews with the students; It is planned to provide information about acquaintance and research, fill in the scales in 10-15 minutes, make CO measurements, and also conduct an average of 20-40 minutes of motivational interviews in the intervention group. In the second interview in the 1st month, it is planned to summarize the first interview, fill in the scales in 3-5 minutes, make the CO measurements in 10-15 minutes or get the measurement results and apply motivational interview in the average of 20-40 minutes. In the third interview in the 3rd month, it is planned to summarize the second interview in 3-5 min, fill in the scales in 10-15 minutes, make CO measurements or get the measurement results and to apply motivational interviews for an average of 20-40 minutes. In the last interview in the 6th month, it is planned to summarize the 3rd-month interview, to apply the scales for approximately 10-15 minutes, to make CO measurements or to get the measurement results.
Study: NCT06167083

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning to Estimate Mortality
Description: Using deep learning we try to develop an algorithm and anticipate mortality

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning to Estimate Mortality
Description: Using deep learning we try to develop an algorithm and anticipate mortality
Study: NCT05548088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LILRB4 STAR-T cells
Description: Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4and-3followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg。
Study: NCT05554627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Intranasal spray; a dissociative hallucinogen drug used as a general anesthetic and an antidepressant for treatment of depression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Atypical antipsychotic; used in the treatment of schizophrenia and bipolar disorder. Other uses include as an add-on treatment in major depressive disorder, tic disorders and irritability associated with autism. Taken by mouth or injection into a muscle.
Study: NCT05933538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: The starting dose is 1.5 mg once daily which will be titrated according to the treating psychiatrist who assessing the response with maximum dose of 4.5mg. The dose to be escalated on 2 weekly interval.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants in this will receive either antidepressants including SSRI, SNRI or TCA or for psychotherapy alone or a combination of psychotherapy and antidepressants.
Study: NCT05217810

Intervention type: OTHER
Intervention: Atectura inhalation capsule (150/80ug)
Description: There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.

Intervention type: OTHER
Intervention: Atectura inhalation capsule (150/160ug)
Description: There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.

Intervention type: OTHER
Intervention: Atectura inhalation capsule (150/320ug)
Description: There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT06419712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D (cholecalciferol) supplementation
Description: This clinical pilot study administered and compared daily and bolus dosing regi-mens of vitamin D to achieve and maintain optimal serum levels of 25(OH)D in post-COVID patients. The daily dose group received constant and gradual supplementation of cholecalciferol, intended to achieve more stable 25(OH)D levels without peaks. Conversely, the bolus group received a weekly dose that could lead to rapid increases followed by gradual declines in 25(OH)D levels. The Daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D (cholecalciferol) supplementation
Description: This clinical pilot study administered and compared daily and bolus dosing regi-mens of vitamin D to achieve and maintain optimal serum levels of 25(OH)D in post-COVID patients. The daily dose group received constant and gradual supplementation of cholecalciferol, intended to achieve more stable 25(OH)D levels without peaks. Conversely, the bolus group received a weekly dose that could lead to rapid increases followed by gradual declines in 25(OH)D levels. The Daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .
Study: NCT05251259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atuliflapon
Description: Randomised participants will receive Atuliflapon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atuliflapon
Description: Randomised participants will receive Atuliflapon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised participants will receive placebo
Study: NCT05052996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISL
Description: Capsules administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISL
Description: Capsules administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISL
Description: Capsules administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISL
Description: Capsules administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEN
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEN
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEN
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEN
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Tablets administered orally without regard to food
Study: NCT05422066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg on day 1,8,15 for 21 days cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction Chemotherapy: 375mg/sqm, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.